AYTU Valuation

Aytu Biopharma Inc

Add to Watchlist

Advanced Chart

2.370

+0.01(0.424%)1D

Overview
Forecast
Valuation
Earnings

AYTU Relative Valuation

AYTU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AYTU is overvalued; if below, it's undervalued.

Historical Valuation

Aytu Biopharma Inc (AYTU) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.03. The fair price of Aytu Biopharma Inc (AYTU) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：2.38

Fair

-1.52

Trailing

Forward

-1.65

EV/EBITDA

Aytu Biopharma Inc. (AYTU) has a current EV/EBITDA of -1.65. The 5-year average EV/EBITDA is -1.40. The thresholds are as follows: Strongly Undervalued below -21.22, Undervalued between -21.22 and -11.31, Fairly Valued between 8.51 and -11.31, Overvalued between 8.51 and 18.41, and Strongly Overvalued above 18.41. The current Forward EV/EBITDA of -1.65 falls within the Historic Trend Line -Fairly Valued range.

-0.99

EV/EBIT

Aytu Biopharma Inc. (AYTU) has a current EV/EBIT of -0.99. The 5-year average EV/EBIT is 11.97. The thresholds are as follows: Strongly Undervalued below -98.95, Undervalued between -98.95 and -43.49, Fairly Valued between 67.43 and -43.49, Overvalued between 67.43 and 122.89, and Strongly Overvalued above 122.89. The current Forward EV/EBIT of -0.99 falls within the Historic Trend Line -Fairly Valued range.

0.39

Aytu Biopharma Inc. (AYTU) has a current PS of 0.39. The 5-year average PS is 0.46. The thresholds are as follows: Strongly Undervalued below -0.61, Undervalued between -0.61 and -0.08, Fairly Valued between 0.99 and -0.08, Overvalued between 0.99 and 1.53, and Strongly Overvalued above 1.53. The current Forward PS of 0.39 falls within the Historic Trend Line -Fairly Valued range.

-1.61

P/OCF

Aytu Biopharma Inc. (AYTU) has a current P/OCF of -1.61. The 5-year average P/OCF is -0.83. The thresholds are as follows: Strongly Undervalued below -4.88, Undervalued between -4.88 and -2.86, Fairly Valued between 1.19 and -2.86, Overvalued between 1.19 and 3.21, and Strongly Overvalued above 3.21. The current Forward P/OCF of -1.61 falls within the Historic Trend Line -Fairly Valued range.

1.76

P/FCF

Aytu Biopharma Inc. (AYTU) has a current P/FCF of 1.76. The 5-year average P/FCF is -0.06. The thresholds are as follows: Strongly Undervalued below -4.99, Undervalued between -4.99 and -2.53, Fairly Valued between 2.40 and -2.53, Overvalued between 2.40 and 4.87, and Strongly Overvalued above 4.87. The current Forward P/FCF of 1.76 falls within the Historic Trend Line -Fairly Valued range.

Aytu Biopharma Inc (AYTU) has a current Price-to-Book (P/B) ratio of 1.12. Compared to its 3-year average P/B ratio of 0.39 , the current P/B ratio is approximately 186.10% higher. Relative to its 5-year average P/B ratio of 0.52, the current P/B ratio is about 114.91% higher. Aytu Biopharma Inc (AYTU) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -71.19%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -70.35% , the current FCF yield is about -100.00% lower.

1.12

P/B

Median3y

0.39

Median5y

0.52

-9.97

FCF Yield

Median3y

-71.19

Median5y

-70.35

Competitors Valuation Multiple

The average P/S ratio for AYTU's competitors is 0.00, providing a benchmark for relative valuation. Aytu Biopharma Inc Corp (AYTU) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 3.71%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Cellectar Biosciences Inc

Lexaria Bioscience Corp

Performance Decomposition

Market capitalization of AYTU increased by 22.92% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -23.15 to -131.35.

The secondary factor is the Revenue Growth, contributed 3.71%to the performance.

Overall, the performance of AYTU in the past 1 year is driven by Margin Expansion. Which is more sustainable.

3.71%

14.59M → 15.14M

Revenue Growth

467.39%

-23.15 → -131.35

Margin Expansion

-448.18%

0.30 → -1.05

P/E Change

22.92%